<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04106492</url>
  </required_header>
  <id_info>
    <org_study_id>SQ3370-001</org_study_id>
    <secondary_id>2020-0185</secondary_id>
    <nct_id>NCT04106492</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of SQ3370 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Multicenter Phase 1, Open-Label Study of SQ3370 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shasqi, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shasqi, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and preliminary activity&#xD;
      of SQ3370 in patients with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">July 9, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 7, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Escalation Cohorts</measure>
    <time_frame>From start of treatment to approximately 12 weeks</time_frame>
    <description>To determine the Maximum Tolerated Dose, if possible, and/or Recommended Phase 2 Dose of SQ3370</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Expansion Cohorts</measure>
    <time_frame>From first dose to approximately 24 weeks</time_frame>
    <description>To evaluate safety. Defined as type, frequency, severity, timing of onset, duration, and relationship to study drugs of any treatment-emergent adverse events (TEAEs); laboratory abnormalities; vital sign abnormalities; adverse electrocardiogram (ECG) or, ECH/MUGA findings; SAEs; or AEs leading to interruption, modification, or discontinuation of study treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK)</measure>
    <time_frame>From start of treatment to approximately 12 weeks</time_frame>
    <description>To determine Maximum Plasma concentration (Cmax) for SQP33 protodrug and active Dox following SQ3370 treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>From start of treatment to end of follow up or 72 weeks after accrual of the final subject</time_frame>
    <description>Defined as achievement of complete response (CR) or partial response (PR) by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>From start of treatment to end of follow up or 72 weeks after accrual of the final subject</time_frame>
    <description>Defined as the interval from the first documentation of objective response to the earlier of the first documentation of disease progression or death from any cause</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluate level of SQP33 in tumor</measure>
    <time_frame>From start of treatment to approximately 12 weeks</time_frame>
    <description>To determine the level of SQP33 protodrug and active Doxorubicin in tumor tissue</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate Pharmacodynamics (PD)</measure>
    <time_frame>From start of treatment to approximately 12 weeks</time_frame>
    <description>To assess immune response (changes in immune biomarkers) as assessed by PBMCs</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Cohort (10 mLSQL70)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 10 mL of SQL70 biopolymer injected intratumorally on Day 1 of each 21-day cycle into a single lesion and then receive escalating doses of SQP33 protodrug administered IV from Day 1 through Day 5 (5 doses) of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Cohort (20 mLSQL70)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 20 mL of SQL70 biopolymer injected intratumorally on Day 1 of each 21-day cycle into a single lesion and then receive escalating doses of SQP33 protodrug administered IV from Day 1 through Day 5 (5 doses) of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SQL70 biopolymer injected intratumorally on Day 1 of each 21-day cycle into a single lesion as determined in Dose Escalation. Then will receive a lower dose than RP2D of SQP33 protodrug administered IV from Day 1 through Day 5 (5 doses) of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B &amp; C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SQL70 biopolymer injected intratumorally on Day 1 of each 21-day cycle into a single lesion as determined in Dose Escalation. Then will receive the RP2D of SQP33 protodrug administered IV from Day 1 through Day 5 (5 doses) of each 21-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SQ3370</intervention_name>
    <description>SQ3370 consists of 2 components: SQL70, a protodrug-activating biopolymer, and SQP33, a protodrug of Doxorubicin</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B &amp; C</arm_group_label>
    <arm_group_label>Dose Escalation Cohort (10 mLSQL70)</arm_group_label>
    <arm_group_label>Dose Escalation Cohort (20 mLSQL70)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of advanced soft tissue sarcoma or other solid tumors&#xD;
&#xD;
          2. Adequate hematologic, hepatic, renal, and coagulation function&#xD;
&#xD;
          3. ECOG performance status score 0-1&#xD;
&#xD;
          4. Tumor is the type where published clinical data would suggest that anthracyclines have&#xD;
             cytotoxic activity&#xD;
&#xD;
          5. Injectable tumor present&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior exposure to 300 mg/m^2 of Dox HCl or DOXIL / CAELYX Â® or 600 mg/m^2 of&#xD;
             Epirubicin HCl&#xD;
&#xD;
          2. Congestive heart failure (CHF), severe myocardial insufficiency, or cardiac arrhythmia&#xD;
&#xD;
          3. Any of the following within 28 days prior to Cycle 1 Day 1:&#xD;
&#xD;
               -  Major surgery, as defined by the Investigator&#xD;
&#xD;
               -  Radiotherapy&#xD;
&#xD;
               -  Chemotherapy, immunotherapy and/or anticancer therapy (except for small molecule&#xD;
                  kinase inhibitors, which are 6 elimination half-lives)&#xD;
&#xD;
          4. Trastuzumab or trastuzumab emtansine dosed within 7 months prior to Cycle 1 Day 1.&#xD;
&#xD;
          5. Any transfusion within 14 days prior to Cycle 1 Day 1.&#xD;
&#xD;
          6. Pregnant or breast-feeding women.&#xD;
&#xD;
          7. Known active CNS metastases and/or carcinomatous meningitis or symptomatic brain&#xD;
             metastasis. Participants with previously treated brain metastases may participate&#xD;
             provided they are radiologically stable&#xD;
&#xD;
          8. History of allergic reactions attributed to Dox or other anthracyclines, NaHA,&#xD;
             hyaluronic acid, or gram-positive bacterial proteins&#xD;
&#xD;
          9. History or evidence of clinically unstable/uncontrolled disorder, condition, or&#xD;
             disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shasqi Clinical Operations</last_name>
    <phone>415-800-1376</phone>
    <email>clinicalstudies@shasqi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>415-800-1376</phone>
      <email>clinicalstudies@shasqi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarcoma Oncology Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>415-800-1376</phone>
      <email>clinicalstudies@shasqi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>415-800-1376</phone>
      <email>clinicalstudies@shasqi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>415-800-1376</phone>
      <email>clinicalstudies@shasqi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek Subbiah, MD</last_name>
      <phone>713-563-0393</phone>
      <email>VSubbiah@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>415-800-1376</phone>
      <email>clinicalstudies@shasqi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>415-800-1376</phone>
      <email>clinicalstudies@shasqi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Research Institute</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>415-800-1376</phone>
      <email>clinicalstudies@shasqi.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2019</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sarcoma</keyword>
  <keyword>Cancer</keyword>
  <keyword>Tumor</keyword>
  <keyword>Soft Tissue Sarcoma</keyword>
  <keyword>Solid Tumor</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Intratumoral</keyword>
  <keyword>Anthracycline</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Esophageal Cancer</keyword>
  <keyword>Precision Oncology</keyword>
  <keyword>Precision Chemotherapy</keyword>
  <keyword>Local Cancer Therapy</keyword>
  <keyword>Targeted Cancer Therapy</keyword>
  <keyword>Bladder Cancer</keyword>
  <keyword>Gastric Tumor</keyword>
  <keyword>Skin Cancer</keyword>
  <keyword>Melanoma</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

